NEW YORK GENOME CENTER INC: Form 990, tax year 2020

View the entire original 990 at ProPublica ↗

Organization: NEW YORK GENOME CENTER INC (EIN 80-0631734)
Tax period: 2020-01-01 to 2020-12-31
Filed: 2021-11-11
IRS object ID: 202113159349300721
Schema version: 2020v4.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule I
Schedule J
Schedule L
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2021-11-11T07:48:08-06:00	ReturnTs
Tax Period End	2020-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	135565207	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	KPMG LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	1305 WALT WHITMAN ROAD	AddressLine1Txt
City	MELVILLE	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	11747	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2020-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	800631734	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	NEW YORK GENOME CENTER INC	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	NEWY	BusinessNameControlTxt
Phone	6469777000	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS 7TH FL	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	MARIA JOANTA	PersonNm
Person Title	CHIEF FINANCIAL OFFICER	PersonTitleTxt
Phone	6469777000	PhoneNum
Signature	2021-11-10	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	MARIA	PersonFirstNm
Person Last	JOANTA	PersonLastNm

Field	Value	IRS element (for citing)
SSN	999009999	SSN

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	ROBERT A ROBINSON	PreparerPersonNm
PTIN	P00741489	PTIN
Phone	2127589700	PhoneNum
Preparation	2021-11-09	PreparationDt

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

Field	Value	IRS element (for citing)
Trusted Customer	3	TrustedCustomerCd
Authentication Assurance Level	AAL1	AuthenticationAssuranceLevelCd
Identity Assurance Level	IAL1	IdentityAssuranceLevelCd

Field	Value	IRS element (for citing)
Tax	2020	TaxYr
Build TS	2022-09-23 18:48:47Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	TOM MANIATIS	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$64,191,532	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.NYGENOME.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	2010	FormationYr
Legal Domicile State	DE	LegalDomicileStateCd
Activity Or Mission	ADVANCING GENOMIC RESEARCH TO DRIVE NOVEL BIOMEDICAL DISCOVERIES TO IMPROVE HUMAN HEALTH	ActivityOrMissionDesc
Voting Members Governing Body	25	VotingMembersGoverningBodyCnt
Voting Members Independent	23	VotingMembersIndependentCnt
Total Employee	172	TotalEmployeeCnt
Total Volunteers	23	TotalVolunteersCnt
Total Gross UBI	$1,507,216	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$32,878,926	PYContributionsGrantsAmt
CY Contributions Grants	$51,639,109	CYContributionsGrantsAmt
PY Program Service Revenue	$9,402,354	PYProgramServiceRevenueAmt
CY Program Service Revenue	$8,497,659	CYProgramServiceRevenueAmt
PY Investment Income	$174,909	PYInvestmentIncomeAmt
CY Investment Income	$90,496	CYInvestmentIncomeAmt
PY Other Revenue	-$211,744	PYOtherRevenueAmt
CY Other Revenue	$556,725	CYOtherRevenueAmt
PY Total Revenue	$42,244,445	PYTotalRevenueAmt
CY Total Revenue	$60,783,989	CYTotalRevenueAmt
PY Grants And Similar Paid	$1,899,777	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$1,010,263	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$28,935,750	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$28,728,885	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$129,829	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$2,325	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$900,402	CYTotalFundraisingExpenseAmt
PY Other Expenses	$49,234,412	PYOtherExpensesAmt
CY Other Expenses	$42,564,807	CYOtherExpensesAmt
PY Total Expenses	$80,199,768	PYTotalExpensesAmt
CY Total Expenses	$72,306,280	CYTotalExpensesAmt
PY Revenues Less Expenses	-$37,955,323	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$11,522,291	CYRevenuesLessExpensesAmt
Total Assets BOY	$97,126,046	TotalAssetsBOYAmt
Total Assets EOY	$83,547,232	TotalAssetsEOYAmt
Total Liabilities BOY	$49,651,789	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$47,595,266	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$47,474,257	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$35,951,966	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$53,028,623	ExpenseAmt
Grant	$1,010,110	GrantAmt
Revenue	$5,514,656	RevenueAmt
Desc	RESEARCH AND RESEARCH SEQUENCING: NYGC'S RESEARCH SCIENTISTS AND FACULTY CONDUCT RESEARCH INTO THE GENETIC FACTORS THAT CONTRIBUTE TO HUMAN DISEASE, BOTH IN THEIR OWN PROJECTS AND THROUGH COLLABORATIONS. NYGC RESEARCHERS HAVE PROJECTS UNDERWAY IN CANCER, INCLUDING LUNG, LIVER, BREAST AND MELANOMA, A MULTISITE VERY RARE CANCER PROJECT AND A LARGE COLLABORATIVE PROJECT STUDYING CANCER IN UNDERSERVED POPULATIONS IN NYC; NEURODEGENERATIVE DISEASES, INCLUDING ALS AND DEMENTIA AND NEUROPSYCHIATRIC DISEASES, FOCUSING ON AUTISM, AMONG OTHERS. IN 2020, NYGC SEQUENCED OVER 8,300 WHOLE GENOME SAMPLES, COMPLETED 396 PROJECTS, AND COLLABORATED WITH 82 INVESTIGATORS FROM 41 INSTITUTIONS WORLDWIDE. FOR MORE INFORMATION SEE SCHEDULE O.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$4,471,789	ExpenseAmt
Revenue	$1,475,787	RevenueAmt
Desc	CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$57,500,412	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	0	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	Yes (1)	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	Yes (1)	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	0	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	Yes (1)	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	57	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	172	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (1)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (1)	Form990TFiledInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	0	QuidProQuoContributionsInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	Yes (1)	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	25	GoverningBodyVotingMembersCnt
Independent Voting Member	23	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	Yes (1)	MembersOrStockholdersInd
Election Of Board Members	Yes (1)	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	LA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
Other Website	Yes (X)	OtherWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	NANCY KONG	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	6469777154	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	101 AVENUE OF THE AMERICAS 7TH FL	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10013	ZIPCd

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	Yes (X)	InfoInScheduleOPartVIIInd

Form990 Part VII Section A Form990PartVIISectionAGrp (38 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
CHERYL A MOORE
PRESIDENT & COO	40.00	Yes (X)	Yes (X)	$1,429,739	$0	$22,317
TOM MANIATIS PHD
SCIENTIFIC DIRECTOR & CEO	40.00	Yes (X)	Yes (X)	$488,963	$0	$149,133
DAFNA BAR-SAGI PHD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
RUSSELL L CARSON MBA
DIRECTOR & CO-CHAIR	4.00	Yes (X)	Yes (X)	$0	$0	$0
ELI CASDIN
DIRECTOR	1.00	Yes (X)		$0	$0	$0
DENNIS S CHARNEY MD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
AUGUSTINE MK CHOI MD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
NICHOLAS DONOFRIO
DIRECTOR	1.00	Yes (X)		$0	$0	$0
JOHN B EHRENKRANZ
DIRECTOR	1.00	Yes (X)		$0	$0	$0
ANTHONY B EVNIN PHD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
LEE GOLDMAN MD MPH
DIRECTOR	1.00	Yes (X)		$0	$0	$0
WESLIE R JANEWAY
DIRECTOR	1.00	Yes (X)		$0	$0	$0
KENNETH KAUSHANSKY MD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
RICHARD P LIFTON MD PHD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
EDISON T LIU MD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
HERB PARDES MD
DIRECTOR & VICE CHAIR	1.00	Yes (X)		$0	$0	$0
FRANK E RICHARDSON MA JD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
IVAN G SEIDENBERG MBA
DIRECTOR & CO-CHAIR	4.00	Yes (X)	Yes (X)	$0	$0	$0
FRANK V SICA
DIRECTOR & COMMITTEE CHAIR	1.00	Yes (X)		$0	$0	$0
JIM SIMONS PHD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
STEVEN D SINGER ESQ
DIRECTOR	1.00	Yes (X)		$0	$0	$0
BRUCE STILLMAN PHD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
CRAIG B THOMPSON MD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
GORDON F TOMASELLI MD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
KEVIN J TRACEY MD
DIRECTOR	1.00	Yes (X)		$0	$0	$0
ELIZABETH BROOKS O'BRIEN
VP & GENERAL COUNSEL	40.00		Yes (X)	$428,773	$0	$46,210
ANA LUCIA BASTIANI-POSNER
SVP, FIN & ADMIN (THROUGH 6/20)	40.00		Yes (X)	$281,437	$0	$17,802
THOMAS LEHNER
SCI DIR, NEURO DIS GEN (AS OF 1/20)	40.00			$460,831	$0	$32,248	Yes (X)
SOREN GERMER
SVP, GENOME TECHNOLOGIES	40.00			$422,326	$0	$33,088	Yes (X)
CAROL ASHE
CHIEF BUSINESS OFFICER	40.00			$414,579	$0	$17,217	Yes (X)
KATHLEEN MCGOVERN KEARNS
VP, DEV'T & CO (THROUGH 11/20)	40.00			$357,657	$0	$31,771	Yes (X)
CHARLES GAGNON
SENIOR DIR, IT INFRASTRUCTURE	40.00			$324,054	$0	$44,932	Yes (X)
MICHAEL CHARLES ZODY
SCIENTIFIC DIR, COMP BIOLOGY	40.00			$198,743	$0	$18,441	Yes (X)
SHAILAJA GARGEYA
SENIOR DIR, SOFTWARE ENGINEER	40.00			$317,700	$0	$18,567		Yes (X)
DAYNA M OSCHWALD
CHIEF OF STAFF	40.00			$263,782	$0	$30,448		Yes (X)
CHRISTOPHER PHIFER BLACK
DIRECTOR, RESEARCH COMPUTING	40.00			$212,125	$0	$42,313		Yes (X)
MELISSA PROBER
SENIOR ASSOCIATE COUNSEL	40.00			$236,753	$0	$14,889		Yes (X)
NICOLAS ROBINE
COMPUTATIONAL BIOLOGY	40.00			$209,092	$0	$35,908		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$6,046,554	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$555,284	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	79	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt	Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt	Province Or StateContractorAddress/ForeignAddress/ProvinceOrStateNm	CountryContractorAddress/ForeignAddress/CountryCd	Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd
PJ MECHANICAL SERVICE & MAINTENANCE CO
55 BROAD STREET	NEW YORK	NY	10004	ENGINEERING SERVICES	$885,590
GUARDIAN SERVICE INDUSTRIES INC
88005 EXPEDITE WAY	CHICAGO	IL	60695	CLEANING SERVICES	$411,466
TEC SYSTEMS INC
47-25 34TH STREET 4TH FLOOR	LONG ISLAND CITY	NY	11101	MAINTENANCE SERVICES	$208,871
STOECKIUS RIGHTS AB
				CONSULTING SERVICES	$164,905	MARIA PRASTGARDSGATA 28 APT 1401	STOCKHOLM	SW	11852
HAROLD VARMUS
450 WEST END AVE 17A	NEW YORK	NY	10024	CONSULTING SERVICES	$150,000

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	7	CntrctRcvdGreaterThan100KCnt
Membership Dues	$3,060,000	MembershipDuesAmt
Government Grants	$12,907,064	GovernmentGrantsAmt
All Other Contributions	$35,672,045	AllOtherContributionsAmt
Noncash Contributions	$386,423	NoncashContributionsAmt
Total Contributions	$51,639,109	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt
RESEARCH SEQUENCING	541700	$7,021,872	$5,514,656	$1,507,216
CLINICAL SEQUENCING	541700	$1,475,787	$1,475,787

Field	Value	IRS element (for citing)
Total Program Service Revenue	$8,497,659	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$90,496	TotalRevenueColumnAmt
Exclusion	$90,496	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$878,878	TotalRevenueColumnAmt
Exclusion	$878,878	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$2,343,308	RealAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$3,407,543	RealAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	-$1,064,235	RealAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$1,064,235	TotalRevenueColumnAmt
Exclusion	-$1,064,235	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp

Field	Value	IRS element (for citing)
Desc	OTHER MISC REVENUE	Desc
Business	900099	BusinessCd
Total Revenue Column	$742,082	TotalRevenueColumnAmt
Exclusion	$742,082	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$742,082	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$60,783,989	TotalRevenueColumnAmt
Related Or Exempt Func Income	$6,990,443	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$1,507,216	UnrelatedBusinessRevenueAmt
Exclusion	$647,221	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$981,757	TotalAmt
Program Services	$981,757	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$28,506	TotalAmt
Program Services	$28,506	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$6,629,835	TotalAmt
Program Services	$2,961,706	ProgramServicesAmt
Management And General	$3,278,702	ManagementAndGeneralAmt
Fundraising	$389,427	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$112,969	TotalAmt
Program Services	$112,969	ProgramServicesAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$17,631,050	TotalAmt
Program Services	$12,445,884	ProgramServicesAmt
Management And General	$4,879,642	ManagementAndGeneralAmt
Fundraising	$305,524	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$1,156,157	TotalAmt
Program Services	$781,519	ProgramServicesAmt
Management And General	$363,311	ManagementAndGeneralAmt
Fundraising	$11,327	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,247,693	TotalAmt
Program Services	$1,101,307	ProgramServicesAmt
Management And General	$142,149	ManagementAndGeneralAmt
Fundraising	$4,237	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$1,951,181	TotalAmt
Program Services	$1,450,058	ProgramServicesAmt
Management And General	$487,640	ManagementAndGeneralAmt
Fundraising	$13,483	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$312,871	TotalAmt
Management And General	$312,871	ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$144,638	TotalAmt
Management And General	$144,638	ManagementAndGeneralAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$2,325	TotalAmt
Fundraising	$2,325	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$2,842,691	TotalAmt
Program Services	$2,768,019	ProgramServicesAmt
Management And General	$74,672	ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$302,467	TotalAmt
Program Services	$94,848	ProgramServicesAmt
Management And General	$205,985	ManagementAndGeneralAmt
Fundraising	$1,634	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$2,454,834	TotalAmt
Program Services	$2,150,989	ProgramServicesAmt
Management And General	$303,845	ManagementAndGeneralAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$268,140	TotalAmt
Program Services	$268,140	ProgramServicesAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$13,746,760	TotalAmt
Program Services	$11,221,311	ProgramServicesAmt
Management And General	$2,406,317	ManagementAndGeneralAmt
Fundraising	$119,132	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$83,962	TotalAmt
Program Services	$71,420	ProgramServicesAmt
Management And General	$10,993	ManagementAndGeneralAmt
Fundraising	$1,549	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$34,967	TotalAmt
Program Services	$24,179	ProgramServicesAmt
Management And General	$9,803	ManagementAndGeneralAmt
Fundraising	$985	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$461,726	TotalAmt
Program Services	$255,030	ProgramServicesAmt
Management And General	$203,479	ManagementAndGeneralAmt
Fundraising	$3,217	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$7,805,926	TotalAmt
Program Services	$7,307,825	ProgramServicesAmt
Management And General	$459,831	ManagementAndGeneralAmt
Fundraising	$38,270	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$391,158	TotalAmt
Management And General	$391,158	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
DIRECT COST OF SEQUENCI	$10,746,255	$10,746,255
RESEARCH	$2,510,045	$2,510,045
OTHER	$346,283	$142,560	$194,431	$9,292
RECRUITMENT	$112,084	$76,085	$35,999

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$72,306,280	TotalAmt
Program Services	$57,500,412	ProgramServicesAmt
Management And General	$13,905,466	ManagementAndGeneralAmt
Fundraising	$900,402	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$11,828,949	BOYAmt
EOY	$9,393,791	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$6,037,230	BOYAmt
EOY	$4,575,195	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$5,125,099	BOYAmt
EOY	$4,431,588	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$2,964,323	BOYAmt
EOY	$1,246,622	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$3,956,650	BOYAmt
EOY	$3,918,628	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$131,310,735	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$80,043,514	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$57,671,401	BOYAmt
EOY	$51,267,221	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$9,542,394	BOYAmt
EOY	$8,714,187	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$97,126,046	BOYAmt
EOY	$83,547,232	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$6,109,365	BOYAmt
EOY	$6,075,510	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$10,610,221	BOYAmt
EOY	$11,521,530	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$2,144,347	BOYAmt
EOY	$71,442	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$4,820,000	BOYAmt
EOY	$4,820,000	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$25,967,856	BOYAmt
EOY	$25,106,784	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$49,651,789	BOYAmt
EOY	$47,595,266	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$40,350,629	BOYAmt
EOY	$27,915,254	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$7,123,628	BOYAmt
EOY	$8,036,712	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$47,474,257	BOYAmt
EOY	$35,951,966	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$97,126,046	BOYAmt
EOY	$83,547,232	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$11,522,291	ReconcilationRevenueExpnssAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$94,901,046	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$70,723,214	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$115,038,771	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$32,878,926	CurrentTaxYearMinus1YearAmt
Current Tax Year	$51,639,109	CurrentTaxYearAmt
Total	$365,181,066	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$94,901,046	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$70,723,214	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$115,038,771	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$32,878,926	CurrentTaxYearMinus1YearAmt
Current Tax Year	$51,639,109	CurrentTaxYearAmt
Total	$365,181,066	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$161,309,349	SubstantialContributorsTotAmt
Public Support Total170	$203,871,717	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$302,728	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$378,725	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$2,090,669	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$3,205,975	CurrentTaxYearMinus1YearAmt
Current Tax Year	$3,312,682	CurrentTaxYearAmt
Total	$9,290,779	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$58,024	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$95,299	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$104,653	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$38,049	CurrentTaxYearMinus1YearAmt
Current Tax Year	$742,082	CurrentTaxYearAmt
Total	$1,038,107	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$375,509,952	TotalSupportAmt
Gross Receipts Rltd Activities	$91,868,129	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.54290	PublicSupportCY170Pct
Public Support PY170	0.56490	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	0	VolunteersInd
Paid Staff Or Management	Yes (1)	PaidStaffOrManagementInd
Media Advertisements	0	MediaAdvertisementsInd
Mailings Members	Yes (1)	MailingsMembersInd
Mailings Members	$509	MailingsMembersAmt
Publications Or Broadcast	0	PublicationsOrBroadcastInd
Grants Other Organizations	0	GrantsOtherOrganizationsInd
Direct Contact Legislators	0	DirectContactLegislatorsInd
Rallies Demonstrations	0	RalliesDemonstrationsInd
Other Activities	Yes (1)	OtherActivitiesInd
Other Activities	$1,500	OtherActivitiesAmt
Total Lobbying Expenditures	$2,009	TotalLobbyingExpendituresAmt
Not Described Section501c3	0	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART II-B, LINE 1:	FormAndLineReferenceDesc
Explanation	SCHEDULE C, PART II-B, LINES 1G & 1I THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES AT THE STATE AND LOCAL LEVEL FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2020, THE NYGC RECEIVED DONATED LOBBYING SERVICES TO ENGAGE WITH NEW YORK STATE GOVERNMENT AGENCIES. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE MEDICAL RESEARCH COMMUNITY; $1,500 OF THE DUES THAT NYGC PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING IN 2020. ADDITIONALLY, NYGC STAFF MAY, FROM TIME TO TIME, CONTACT FEDERAL LEGISLATORS OR THEIR STAFF TO ENCOURAGE THEIR SUPPORT FOR MATTERS OF CONCERN TO THE ACADEMIC MEDICAL RESEARCH COMMUNITY. SUCH CONTACT MAY INCLUDE WRITING LETTERS OR OCCASIONAL MEETINGS WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH NYGC'S COMMUNICATIONS WITH THE FEDERAL GOVERNMENT IN 2020 IS $509.	ExplanationTxt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$71,040,084	OtherCostOrOtherBasisAmt
Depreciation	$22,750,883	DepreciationAmt
Book Value	$48,289,201	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$58,774,557	OtherCostOrOtherBasisAmt
Depreciation	$55,797,955	DepreciationAmt
Book Value	$2,976,602	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,496,094	OtherCostOrOtherBasisAmt
Depreciation	$1,494,676	DepreciationAmt
Book Value	$1,418	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$51,267,221	TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp (2 entries)

DescDesc	Book ValueBookValueAmt
SECURITY DEPOSITS	$8,255,470
DEFERRED COMPENSATION	$458,717

Field	Value	IRS element (for citing)
Total Book Value Other Assets	$8,714,187	TotalBookValueOtherAssetsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

Field	Value	IRS element (for citing)
Desc	DEFERRED RENT	Desc
Amt	$25,106,784	Amt

Field	Value	IRS element (for citing)
Total Liability	$25,106,784	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$64,191,532	TotalRevEtcAuditedFinclStmtAmt
Revenue Not Reported	$0	RevenueNotReportedAmt
Revenue Subtotal	$64,191,532	RevenueSubtotalAmt
Other Revenues Not Included	-$3,407,543	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	-$3,407,543	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$60,783,989	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$75,713,823	TotExpnsEtcAuditedFinclStmtAmt
Other Expenses Included	$3,407,543	OtherExpensesIncludedAmt
Expenses Not Reported	$3,407,543	ExpensesNotReportedAmt
Expenses Subtotal	$72,306,280	ExpensesSubtotalAmt
Expenses Not Rpt Fincl Stmt	$0	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$72,306,280	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART X, LINE 2:	NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2020 AND 2019.
PART XI, LINE 4B - OTHER ADJUSTMENTS:	RENTAL EXPENSE -3,407,543.
PART XII, LINE 2D - OTHER ADJUSTMENTS:	RENTAL EXPENSE 3,407,543.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)

RegionRegionTxt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
ASIA	1	PROGRAM SERVICES	RESEARCH	$499
EUROPE	12	PROGRAM SERVICES	RESEARCH	$365,582
EUROPE	1	PROGRAM SERVICES	COLLABORATION	$28,506
NORTH AMERICA	4	PROGRAM SERVICES	RESEARCH	$120,223

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	18	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	18	TotalEmployeeCnt
Subtotal Spent	$514,810	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$514,810	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp

Field	Value	IRS element (for citing)
Region	EUROPE	RegionTxt
Purpose Of Grant	RESEARCH SUBAWARD	PurposeOfGrantTxt
Cash Grant	$28,506	CashGrantAmt
Manner Of Cash Disbursement	WIRE	MannerOfCashDisbursementTxt

Field	Value	IRS element (for citing)
Total501c3 Org	1	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 2:	NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT.
PART I, LINE 3:	THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD.
PART III ACCOUNTING METHOD:

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	0	GrantRecordsMaintainedInd

Recipient Table RecipientTable (11 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
UNIVERSITY OF WASHINGTON
129 SCHMITZ HALL 355870	SEATTLE	WA	98195	916001537	WA	$180,007	RESEARCH SUBAWARD
WEILL CORNELL MEDICAL COLLEGE
1300 YORK AVENUE	NEW YORK	NY	10065	150532082	501(C) (3)	$177,332	RESEARCH SUBAWARD
COLD SPRING HARBOR LABORATORY
ONE BUNGTOWN ROAD	COLD SPRING HARBOR	NY	11724	112013303	501(C)(3)	$148,428	RESEARCH SUBAWARD
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE	NEW YORK	NY	10029	136171197	501(C) (3)	$100,743	RESEARCH SUBAWARD
COLUMBIA UNIVERSITY
615 WEST 131ST STREET	NEW YORK	NY	10027	135598093	501(C) (3)	$93,023	RESEARCH SUBAWARD
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
700 ROSEDALE AVENUE CB 1034	ST LOUIS	MO	63112	430653611	501(C) (3)	$78,871	RESEARCH SUBAWARD
MGH RESEARCH
399 REVOLUTION DRIVE	SOMERVILLE	MA	02145	042697983	501(C) (3)	$67,059	RESEARCH SUBAWARD
THE BROAD INSTITUTE INC
415 MAIN STREET	CAMBRIDGE	MA	02142	263428781	501(C) (3)	$63,648	RESEARCH SUBAWARD
JOHNS HOPKINS UNIVERSITY
3910 KESWICK ROAD	BALTIMORE	MD	21211	520595110	501(C) (3)	$47,759	RESEARCH SUBAWARD
NEW YORK UNIVERSITY
105 E 17TH STREET	NEW YORK	NY	10003	135562308	501(C) (3)	$13,278	RESEARCH SUBAWARD
MEMORIAL SLOAN KETTERING CANCER CENTER
1275 YORK AVENUE	NEW YORK	NY	10065	131924236	501(C) (3)	$11,608	RESEARCH SUBAWARD

Field	Value	IRS element (for citing)
Total501c3 Org	11	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Idemnification Gross Up Pmts	Yes (X)	IdemnificationGrossUpPmtsInd
Housing Allowance Or Residence	Yes (X)	HousingAllowanceOrResidenceInd
Written Policy Ref T And E Expnss	Yes (1)	WrittenPolicyRefTAndEExpnssInd
Substantiation Required	Yes (1)	SubstantiationRequiredInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (15 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
CHERYL A MOORE
PRESIDENT & COO	$922,497	$0	$223,725	$0	$283,517	$0	$17,100	$0	$5,217	$0	$1,452,056	$0	$0	$0
TOM MANIATIS PHD
SCIENTIFIC DIRECTOR & CEO	$488,963	$0	$0	$0	$0	$0	$0	$0	$149,133	$0	$638,096	$0	$0	$0
THOMAS LEHNER
SCI DIR, NEURO DIS GEN (AS OF 1/20)	$370,780	$0	$50,000	$0	$40,051	$0	$17,006	$0	$15,242	$0	$493,079	$0	$0	$0
ELIZABETH BROOKS O'BRIEN
VP & GENERAL COUNSEL	$428,773	$0	$0	$0	$0	$0	$17,100	$0	$29,110	$0	$474,983	$0	$0	$0
SOREN GERMER
SVP, GENOME TECHNOLOGIES	$390,826	$0	$31,500	$0	$0	$0	$17,100	$0	$15,988	$0	$455,414	$0	$0	$0
CAROL ASHE
CHIEF BUSINESS OFFICER	$414,579	$0	$0	$0	$0	$0	$17,100	$0	$117	$0	$431,796	$0	$0	$0
KATHLEEN MCGOVERN KEARNS
VP, DEV'T & CO (THROUGH 11/20)	$333,954	$0	$0	$0	$23,703	$0	$17,100	$0	$14,671	$0	$389,428	$0	$0	$0
CHARLES GAGNON
SENIOR DIR, IT INFRASTRUCTURE	$281,505	$0	$42,549	$0	$0	$0	$16,642	$0	$28,290	$0	$368,986	$0	$0	$0
SHAILAJA GARGEYA
SENIOR DIR, SOFTWARE ENGINEER	$309,918	$0	$7,782	$0	$0	$0	$17,100	$0	$1,467	$0	$336,267	$0	$0	$0
ANA LUCIA BASTIANI-POSNER
SVP, FIN & ADMIN (THROUGH 6/20)	$216,108	$0	$40,300	$0	$25,029	$0	$16,935	$0	$867	$0	$299,239	$0	$0	$0
DAYNA M OSCHWALD
CHIEF OF STAFF	$248,782	$0	$15,000	$0	$0	$0	$14,460	$0	$15,988	$0	$294,230	$0	$0	$0
CHRISTOPHER PHIFER BLACK
DIRECTOR, RESEARCH COMPUTING	$212,125	$0	$0	$0	$0	$0	$13,298	$0	$29,015	$0	$254,438	$0	$0	$0
MELISSA PROBER
SENIOR ASSOCIATE COUNSEL	$236,753	$0	$0	$0	$0	$0	$14,237	$0	$652	$0	$251,642	$0	$0	$0
NICOLAS ROBINE
COMPUTATIONAL BIOLOGY	$209,092	$0	$0	$0	$0	$0	$12,823	$0	$23,085	$0	$245,000	$0	$0	$0
MICHAEL CHARLES ZODY
SCIENTIFIC DIR, COMP BIOLOGY	$198,743	$0	$0	$0	$0	$0	$9,998	$0	$8,443	$0	$217,184	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

PART I, LINE 1A

TAX INDEMNIFICATION AND GROSS-UP PAYMENTS NYGC PAID TAXES ON BEHALF OF ITS PRESIDENT & CHIEF OPERATING OFFICER (COO) VIA A PAYROLL TAX GROSS UP FOR LIFE INSURANCE, DISABILITY AND LONG-TERM CARE BENEFITS PURSUANT TO HER OFFER LETTER. AN EXECUTIVE COMPENSATION COMMITTEE OF INDEPENDENT BOARD MEMBERS WAS RESPONSIBLE FOR ESTABLISHING HER COMPENSATION PACKAGE, WHICH WAS THEN APPROVED BY THE BOARD OF DIRECTORS. HOUSING ALLOWANCE OR RESIDENCE FOR PERSONAL USE NYGC SELECTIVELY OFFERS HOUSING ALLOWANCES TO EMPLOYEES, PRINCIPALLY AS A RECRUITING TOOL FOR NEW FACULTY AND POSTDOCTORAL FELLOWS. SUBSIDIZED HOUSING OR HOUSING ALLOWANCES ARE COMMONLY OFFERED BY PEER ACADEMIC INSTITUTIONS IN NEW YORK CITY TO HELP FACULTY AND OTHER RESEARCHERS DEFRAY THE HIGH COST OF HOUSING. THE VALUE OF THIS ASSISTANCE WAS TREATED AS TAXABLE COMPENSATION TO THE EMPLOYEE.

PART I, LINE 3

IN 2020, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN LATE 2019, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. RESULTS OF THIS STUDY WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2020 AND THE COMMITTEE DISCUSSED THEM. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO, WAS REASONABLE.

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Field	Value	IRS element (for citing)
Person	SILAS MANIATIS	PersonNm

Field	Value	IRS element (for citing)
Relationship Description	FAMILY MEMBER OF DIRECTOR	RelationshipDescriptionTxt
Transaction	$112,696	TransactionAmt
Transaction	SALARY	TransactionDesc
Sharing Of Revenues	0	SharingOfRevenuesInd

Schedule M IRS990ScheduleM

Drugs And Medical Supplies DrugsAndMedicalSuppliesGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	1	ContributionCnt
Noncash Contributions Rpt F990	$386,423	NoncashContributionsRptF990Amt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	0	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, COLUMN (B):	FormAndLineReferenceDesc
Explanation	THE NUMBER REPORTED IN PART I, COLUMN B REPRESENTS THE NUMBER OF CONTRIBUTIONS.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (11 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART I, LINE 1 & PART III, LINE 1:	NYGC IS ORGANIZED AND OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, DEDICATED TO STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH, SEQUENCING AND BIOINFORMATICS, WHOSE MEMBERS INCLUDE LEADING ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS. NYGC ADVANCES GENOMICS THROUGH THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL METHODS AND THE APPLICATION OF THESE METHODS TO DISEASE-FOCUSED RESEARCH TO ENHANCE OUR UNDERSTANDING OF THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE AND NEUROPSYCHIATRIC DISEASE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD. (II) RECRUITING AND RETAINING WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGC'S SCIENTIFIC RESEARCH PROGRAMS; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) ADVANCING GENOMIC RESEARCH TO DRIVE NOVEL BIOMEDICAL DISCOVERIES TO IMPROVE HUMAN HEALTH; (VI) STRIVING TO MAXIMIZE THE BENEFITS OF OUR RESEARCH AND INNOVATION FOR DIVERSE COMMUNITIES; (VII) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; (VIII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, OR RELIGION, AND (IX) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES.
FORM 990, PART III, LINE 4A & LINE 4B	NYGC IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION WITH THE MISSION OF IMPROVING HUMAN HEALTH THROUGH TRANSFORMATIVE GENOMIC RESEARCH. NYGC'S WORK BUILDS ON THE EXPERTISE AND EXPERIENCE THAT NYGC HAS DEVELOPED SINCE ITS FOUNDING IN 2011 AND AUGMENTS RESEARCH BEING CONDUCTED BY NYGC MEMBER INSTITUTIONS. COLLABORATING WITH PREMIER ACADEMIC, MEDICAL AND INDUSTRY LEADERS ACROSS THE GLOBE, NYGC IS CONDUCTING DISEASE-BASED GENOMIC RESEARCH IN AREAS WHERE IT HAS DEVELOPED A STRONG AND SUCCESSFUL TRACK RECORD, PARTICULARLY IN NEURODEGENERATIVE DISEASES, SUCH AS ALS; NEUROPSYCHIATRIC DISEASES, PRINCIPALLY IN AUTISM; AND CANCER, FOCUSING ON UNDERSERVED POPULATIONS AND RARE CANCERS, AMONG OTHERS. IN 2020 AND 2021, THE NYGC ALSO HAS EXPANDED ITS EXPERTISE TO COVID-19 RESEARCH. EARLY ON IN THE PANDEMIC, NYGC QUICKLY PIVOTED TO ADDRESSING THE URGENCY OF THE CORONAVIRUS OUTBREAK, WITH OUR FACULTY AND STAFF SCIENTISTS CONDUCTING COVID-19 GENOMICS RESEARCH AND SARS-COV-2 VIRUS TESTING WHILE CONTINUING TO MAKE STRIDES IN OUR CORE RESEARCH AREAS. THROUGH INNOVATIVE RESEARCH AND GENOMIC DISCOVERY, NYGC SERVES AS A VITAL COLLABORATIVE HUB FOR GENOMIC SCIENCE. NYGC, ITS MEMBER INSTITUTIONS AND PARTNERS ARE UNITED IN AN UNPRECEDENTED CLOSE COLLABORATION OF TECHNOLOGY, SCIENCE AND MEDICINE, DESIGNED TO HARNESS THE POWER OF INNOVATION AND GENOMICS TO MAKE GROUNDBREAKING NEW DISCOVERIES IN OUR CORE DISEASE RESEARCH AREAS. THEIR SHARED OBJECTIVE IS THE ACCELERATION OF TRANSLATIONAL MEDICAL GENOMICS TO BENEFIT PATIENTS AROUND THE WORLD. NYGC'S SCIENTIFIC MISSION BUILDS ON THE COLLABORATIVE RESEARCH PROJECTS AMONG NYGC FACULTY MEMBERS AND STAFF SCIENTISTS WITH RESEARCHERS AND CLINICIANS FROM MEMBER INSTITUTIONS, AN AFFILIATE MEMBERSHIP PROGRAM, DISEASE AND TECHNOLOGY-CENTERED WORKING GROUPS AND INDUSTRY PARTNERS. RESEARCH AND FACULTY --------------------- SINCE ITS INCEPTION, NYGC HAS ATTRACTED WORLD-CLASS SCIENTISTS WHOSE GENOMIC EXPERTISE - INCLUDING SINGLE CELL GENOMICS, GENOME ENGINEERING, POPULATION, FUNCTIONAL AND EVOLUTIONARY GENOMICS, TECHNOLOGY AND METHODS DEVELOPMENT, STATISTICS, COMPUTATIONAL BIOLOGY, EPIGENETICS, MACHINE LEARNING AND BIOENGINEERING - ENABLES A MULTIDISCIPLINARY AND IN-DEPTH APPROACH TO THE EVOLVING FIELD OF GENOMICS. NYGC'S FACULTY SUPPORT NYGC'S SCIENTIFIC VISION THROUGH THE ADVANCEMENT OF TECHNOLOGY DEVELOPMENT AND GENOMIC MEDICINE. FACULTY MEMBERS HAVE JOINT APPOINTMENTS AT THE NYGC'S INSTITUTIONAL FOUNDING MEMBERS TO PROMOTE COLLABORATION, STRENGTHEN RESEARCH CAPABILITIES, ADVANCE ACADEMIC LEADERSHIP, AND ENHANCE OUR ABILITY TO UNDERSTAND AND HELP TREAT HUMAN DISEASE. IN 2020, NYGC MANAGED 68 GRANTS INCLUDING FUNDING FROM THE NATIONAL INSTITUTES OF HEALTH (NIH). NYGC'S RESEARCHERS ARE WORKING WITH ITS MEMBER INSTITUTIONS AND COLLABORATIVE PARTNERS TO ADDRESS THE FUNDAMENTAL CHALLENGE IN PRECISION MEDICINE: UNDERSTANDING THE RELATIONSHIP BETWEEN DNA SEQUENCE VARIATION AND MECHANISMS OF HUMAN DISEASE, RANGING FROM CANCER TO AUTISM TO NEURODEGENERATIVE DISEASE. NYGC RESEARCHERS PUBLISHED MORE THAN 50 STUDIES IN LEADING SCIENTIFIC JOURNALS. ACCOMPLISHMENTS IN 2020 INCLUDE: ADVANCING COVID-19 RESEARCH -------------------- IN MARCH OF 2020, THE NYGC LAUNCHED THE COVID-19 GENOMICS RESEARCH NETWORK (CGRN), A NEW MULTIDISCIPLINARY CONSORTIUM WITH THE GOAL OF DEVELOPING COLLABORATIVE RESEARCH PROJECTS WITH THE SCIENTIFIC COMMUNITY TO UNDERSTAND HOW THE SARS-COV-2 VIRUS SPREADS, HOW THE IMMUNE SYSTEM RESPONDS, WHY SOME PEOPLE ARE MINIMALLY AFFECTED WHILE OTHERS ARE SEVERELY IMPACTED, AND WHICH PHARMACEUTICAL STRATEGIES MIGHT OPTIMALLY HELP REDUCE THE SPREAD AND ALLEVIATE SYMPTOMS. A CHIEF GOAL OF THE CGRN IS TO COMBINE CLINICAL AND GENOMIC DATA GENERATED FROM PATIENTS IN AN NYGC-HOSTED DATA COMMONS FOR PARTICIPATING PHYSICIANS AND SCIENTISTS. THIS RESOURCE WILL HELP SUPPORT ONGOING EFFORTS TO IMPROVE TREATMENT OF PATIENTS AND FURTHER STUDIES TO UNDERSTAND THE DISEASE, EVOLUTION OF THE VIRUS, AND LONG-TERM IMPACT ON POPULATION HEALTH. CGRN MEETINGS HAVE BECOME A CRITICAL INFOMRATION-SHARING FORUM FOR THE WORLDWIDE COVID-19 GENOMICS COMMUNITY, WITH UP TO 250 RESEARCHERS AND CLINICIANS FROM AROUND THE GLOBE REGULARLY ATTENDING THESE VIRTUAL MEETINGS. AS PART OF THE CGRN, NYGC IS SEQUENCING COVID VIRAL AND HOST SAMPLES FOR SEVERAL COLLABORATIVE COVID-19 RESEARCH PROJECTS WITH OUR INSTITUTIONAL MEMBERS. IN MAY 2020, A UNIQUE PARTNERSHIP WAS LAUNCHED BETWEEN THE NY STATE DEPARTMENT OF HEALTH, THE NYGC, AND THE ROCKEFELLER UNIVERSITY TO BETTER UNDERSTAND COVID-19 RELATED ILLNESS IN CHILDREN. THE NYGC IS ALSO ONE OF 50 SEQUENCING HUBS INVOLVED IN THE INTERNATIONAL COVID HUMAN GENETIC EFFORT, LED BY JEAN-LAURENT CASANOVA, MD, PHD, AT THE ROCKEFELLER UNIVERSITY AND HELEN SU, MD, PHD, AT THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASE. NYGC'S FACULTY QUICKLY PIVOTED TO FOCUS THEIR EXPERTISE ON SARS-COV-2 RESEARCH IN ADDITION TO THEIR PRIMARY AREAS OF EXPERTISE. NYGC CORE FACULTY MEMBER NEVILLE SANJANA, PHD, AND HIS COLLEAGUES USED HIGH-THROUGHPUT CRISPR GENE-EDITING TOOLS IN A STUDY TO IDENTIFY WHICH KEY HUMAN GENES ARE REQUIRED BY THE SARS-COV-2 VIRUS TO BETTER UNDERSTAND HOW THE VIRUS DEPENDS ON ITS HOST AND WHETHER THERE ARE EXISTING DRUGS TO TARGET THOSE CRITICAL DEPENDENCIES. THIS STUDY WAS PUBLISHED IN CELL IN OCTOBER OF 2020. IN CLOSE COLLABORATION WITH THE LAB OF BEN TENOEVER, PHD AT MT. SINAI, THE STUDY TEAM PERFORMED A GENOME-SCALE, LOSS-OF-FUNCTION CRISPR SCREEN TO SYSTEMATICALLY KNOCK OUT ALL THE GENES IN THE HUMAN GENOME, IDENTIFYING THE GENES AND THUS POTENTIAL DRUG TARGETS THAT PROTECT AGAINST SARS-COV-2 INFECTION. THE RESEARCHERS USED A BROAD RANGE OF ANALYTICAL AND EXPERIMENTAL METHODS TO VALIDATE THEIR RESULTS, INCLUDING REPURPOSING EXISTING FDA-APPROVED DRUGS TO COMBAT THE VIRUS. CONTRIBUTORS TO THIS INTEGRATIVE STUDY INCLUDE SCIENTISTS FROM NYGC'S TECHNOLOGY INNOVATION LAB, AND THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASES.
FORM 990, PART III, LINE 4A	NEURODEGENERATIVE DISEASE --------------------- THE NYGC'S ALS CONSORTIUM, A GLOBAL COLLABORATION OF CLINICIANS, SCIENTISTS, GENETICISTS, AND COMPUTATIONAL BIOLOGISTS ORGANIZED BY NYGC'S CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), ADDED SIX NEW MEMBERS TO THE CONSORTIUM'S 40 MEMBERS WORLDWIDE. THE MEMBERS THAT JOINED IN 2020 INCLUDE: BROAD INSTITUTE, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, NORTHWELL HEALTH, TEL AVIV SOURASKY MEDICAL CENTER, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), AND THE UNIVERSITY OF CALIFORNIA SAN DIEGO. THROUGH THE DATA-SHARING REPOSITORY MAINTAINED BY THE CGND, THE ALS CONSORTIUM IS DEVELOPING AN EVER-GROWING RESOURCE OF GENOMIC SEQUENCING AND CLINICAL DATA. BY YEAR-END 2020, 3,637 WHOLE GENOMES AND ALMOST 2,000 RNA SAMPLES FROM ALS PATIENTS WERE SEQUENCED AND ANALYZED, MAKING THIS DATASET AVAILABLE TO ALL ALS RESEARCHERS, ONE OF THE LARGEST ALS COHORTS IN THE WORLD. IN DECEMBER, THE MEDICAL RESEARCH FOUNDATION, TARGET ALS, WHICH PROVIDES SUPPORT TO THE CGND AND CONTRIBUTES ALS PATIENT SAMPLES TO ITS REPOSITORY, LAUNCHED THE TARGET ALS DIAGNOSIS INITIATIVE, THE FIRST-EVER COMPREHENSIVE EFFORT TO DISCOVER ALS BIOMARKERS. THIS NEW PROGRAM INCLUDES DEVELOPING AN INTEGRATED BIOFLUID AND GENOMICS CORE MADE POSSIBLE THROUGH EXISTING ALLIANCES BETWEEN TARGET ALS, THE ALS ASSOCIATION AND THE TOW FOUNDATION. THE LAB OF NYGC CORE FACULTY MEMBER DAVID KNOWLES, PHD, WHO JOINED NYGC, WITH A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY IN 2019, DEVELOPED A NEW STATISTICAL TOOL TO IMPROVE ANALYSIS OF BIOBANKS AND USING MACHINE LEARNING TO UNCOVER NOVEL THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE. THE NEW METHOD IMPROVES THE ABILITY TO INFER SPARSE NETWORKS OF DIRECT CAUSAL EFFECTS FROM PHENOME-SCALE GWAS SUMMARY STATISTICS. IN AUGUST, DR. KNOWLES AND COLLABORATOR TOWFIQUE RAJ, PHD, A CORE FACULTY MEMBER AT MT. SINAI'S RONALD M. LOEB CENTER FOR ALZHEIMER'S DISEASE, WERE AWARDED A UO1 GRANT FROM THE NATIONAL INSTITUTES OF HEALTH FOR THEIR PROJECT "LEARNING THE REGULATORY CODE OF ALZHEIMER'S DISEASE." THE TEAM WILL USE MACHINE LEARNING ALGORITHMS AND BUILD COMPUTATIONAL MODELS TO UNCOVER WHICH GENES, PATHWAYS, AND MOLECULAR MECHANISMS ARE INVOLVED IN ALZEHIEMER'S THAT WILL PROVIDE NOVEL THERAPEUTIC TARGETS FOR PATIENTS. NEUROPSYCHIATRIC DISEASE --------------------- THROUGH A $40 MILLION GRANT AWARD FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, A DIVISION OF NIH, IN 2015 THE NYGC CREATED A CENTER FOR COMMON DISEASE GENOMICS, ENGAGED IN LARGE-SCALE WHOLE GENOME SEQUENCING STUDIES OF AUTISM AND OTHER COMPLEX DISEASES. NYGC RESEARCHERS ARE INVOLVED IN SFARI (SIMONS FOUNDATION AUTISM RESEARCH INITIATIVE) AND SPARK (SIMONS FOUNDATION POWERING AUTISM RESEARCH FOR KNOWLEDGE) AND LEAD OR CONTRIBUTE TO AN ARRAY OF OTHER COLLABORATIVE NEUROPSYCHIATRIC DISEASE-RELATED GENOMIC STUDIES. BY YEAR-END OF 2020, THE NYGC ALSO REACHED A SIGNIFICANT MILESTONE IN ITS NEUROPSYCHIATRIC AND NEURODEVELOPMENTAL DISEASE RESEARCH. NYGC TEAMS HAVE NOW SEQUENCED AND ANALYZED OVER 41,000 GENOMES, PRIMARILY OF AUTISM PATIENTS AND THEIR FAMILIES, AS PART OF THE CENTERS FOR COMMON DISEASE GENOMICS PROGRAM. IN JANUARY OF 2020, THOMAS LEHNER PHD, MPH, JOINED THE NYGC AS SCIENTIFIC DIRECTOR OF NEUROPSYCHIATRIC DISEASE GENOMICS TO LEAD THE EXPANSION OF THE NYGC'S NEUROPSYCHIATRIC DISEASE RESEARCH PROGRAM, FOCUSED ON THE GENETIC ARCHITECTURE OF AUTISM, SCHIZOPHRENIA, AND BIPOLAR DISORDER. DR. LEHNER IS PURSUING NEW COLLABORATIVE OPPORTUNITIES BOTH NATIONALLY AND GLOBALLY. HE IS HOSTING A SERIES OF SEMINARS WITH POTENTIAL COLLABORATORS REPRESENTING THE BREADTH OF NEUROPSYCHIATRIC DISEASE GENOMICS. DR. LEHNER, WHO CAME TO THE NYGC FROM A DISTINGUISHED 15-YEAR CAREER AT THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH), HOSTED A VIRTUAL VISIT BY NIMH DIRECTOR JOSHUA A. GORDON, MD, PHD, TO ENGAGE WITH NYGC FACULTY AND STAFF SCIENTISTS AND DISCUSS OPPORTUNITIES FOR COLLABORATION. DR. LEHNER ALSO LEADS NYGC'S NEUROPSYCHIATRIC DISEASE SCIENTIFIC WORKING GROUP. ONE OF THE SIGNATURE PROJECTS OF THIS GROUP IS THE DEVELOPMENT OF A NEW YORK-WIDE PRECISION PSYCHIATRY COHORT THAT WILL INTEGRATE DIAGNOSTIC, DEMOGRAPHIC, AND PATIENT CARE DATA AND OTHER MEDICAL RECORDS TO PROVIDE A PLATFORM FOR SCIENTIFIC DISCORBY, CLINICAL VALIDATIONS, AND TRANSLATIONAL IMPLEMENTATION. CANCER -------------------- GENOMICS-CENTERED INITIATIVES TO ADDRESS CANCER CARE CHALLENGES ARE A KEY FOCUS OF THE GENOME CENTER CANCER GROUP (GCCG), LED BY NOBEL LAUREATE HAROLD VARMUS, MD, SENIOR ASSOCIATE CORE MEMBER, NYGC, AND LEWIS THOMAS UNIVERSITY PROFESSOR OF MEDICINE, WEILL CORNELL MEDICINE, AND CHARLES SAWYERS, MD, CHAIR, HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM, MARIE-JOSE AND HENRY R. KRAVIS CHAIR, MEMORIAL SLOAN KETTERING CANCER CENTER, AND AFFILIATE MEMBER, NYGC. WITHIN THE LAST THREE YEARS, THE GCCG, COMPOSED OF CLINICIANS AND CANCER RESEARCHERS FROM NYGC'S MEMBER INSTITUTIONS, INCLUDING SEVEN NCI-DESIGNATED CANCER CENTERS, HAS DEVELOPED TWO MAJOR MULTI-INSTITUTIONAL COLLABORATIONS. IN 2018, THE GROUP BEGAN WORK ON ITS POLYETHNIC-1000 PROJECT TO STUDY CANCER GENOMES OF UNDERSERVED, ETHNICALLY DIVERSE POPULATIONS. IN 2019, THE GCCG LAUNCHED THE VERY RARE CANCER CONSORTIUM, A NEW COLLABORATION TO HELP ADVANCE CLINICAL CARE FOR PATIENTS AFFECTED BY VERY RARE TUMOR TYPES. THESE PROJECTS ACHIEVED THE FOLLOWING PROGRESS MILESTONES IN 2020: POLYETHNIC-1000 (P-1000), WAS AWARDED ADDITIONAL GRANT FUNDING IN 2020 TO SUPPORT THE PROGRAM, INCLUDING SEVEN NEW MULTI-INSTITUTIONAL CANCER PROJECTS FOCUSED ON UNDERSERVED POPULATIONS. THE AWARD-WINNING NEW PROJECTS WILL INVESTIGATE A VARIETY OF CANCERS INCLUDING PANCREATIC, COLORECTAL, AND ENDOMETRIAL CANCER IN AFRICAN AMERICANS; LUNG CANCER IN ASIAN AMERICAN PATIENTS; BREAST AND PROSTATE CANCER IN PATIENTS OF AFRICAN ANCESTRY; MULTIPLE MYELOMA IN IN AFRICAN AMERICANS; AND THE ROLE OF ETHNICITY IN BLADDER CANCER. THE VERY RARE CANCER CONSORTIUM (VRCC) VIRTUALLY CONVENED ITS MULTI-INSTITUTIONAL MOLECULAR TUMOR BOARD WHERE ONCOLOGISTS, HEMATOLOGISTS, SCIENTISTS, PATHOLOGISTS, COMPUTATIONAL BIOLOGISTS, AND OTHER MEMBERS OF THE CANCER GENOMICS COMMUNITY ON A REGULAR BASIS. CLINICIANS FROM PARTICIPATING HOSPITALS REPORT CASE CONFERENCES TO THE TUMOR BOARD TO DETERMINE THE MOST EFFECTIVE TREATMENT FOR PATIENTS WITH VERY RARE CANCERS. NYGC CORE FACULTY MEMBER MARCIN IMIELINSI, MD, PHD, PUBLISHED A STUDY IN CELL, THAT IDENTIFIED THREE NEW DISTINCT CLASSES OF STRUCTURAL VARIATIONS IN THE DNA OF THOUSANDS OF CANCER SAMPLES ACROSS MULTIPLE CANCER TYPES. THESE DISCOVERIES HELP EXPLAIN DIFFERENT MECHANISMS THAT ENABLE CANCER CELLS TO EXPAND AND GROW RAPIDLY WHILE SIMULTANEOUSLY EVADING NATURAL DEFENSE MECHANISMS AND TREATMENT. THE RESEARCH TEAM IS CONTINUING TO APPLY TO STRUCTURAL VARIANT DETECTION STRATEGY TO CANCER CASES AND EXPECTS THE APPROACH TO BECOME MORE WIDESPREAD IN CLINICS AND IN RESEARCH LABS IN THE FUTURE. NYGC CORE FACULTY MEMBER DAN LANDAU, MD, PHD, AND HIS RESEARCH TEAM HAVE DEVELOPED A WHOLE-GENOME SEQUENCING TECHNOLOGY POWERED BY MACHINE LEARNING THAT IS ABLE TO IDENTIFY VERY LOW LEVELS OF TUMOR DNA IN BLOOD SAMPLES TO ENABLE THE EARLY DETECTION OF CANCER RECURRENCE AFTER SURGERY OR TREATMENT. THE PROOF-OF-CONCEPT DATA OF THIS LANDMARK LIQUID-BIOPSY METHOD WAS PUBLISHED IN NATURE MEDICINE IN JUNE 2020, WITH NYGC COMPUTATIONAL BIOLOGY TEAM MEMBERS ARE AMONG THE CO-AUTHORS.
FORM 990, PART III, LINE 4A	TECHNOLOGY INNOVATION -------------------- IN 2020, THE CENTER FOR INTEGRATED CELLULAR ANALYSIS WAS ESTABLISHED AT THE NYGC. FUNDED THROUGH THE CENTERS OF EXCELLENCE IN GENOMIC SCIENCE PROGRAM OF THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, THE MISSION OF THE CENTER IS TO DEVELOP A COMPREHENSIVE SUITE OF TECHNOLOGIES AND ANALYTICAL METHODS TO MEASURE AND INTEGRATE THE MOLECULAR AND ENVIRONMENTAL DETERMINANTS OF CELLULAR IDENTITY. THIS WILL ADDRESS CRITICAL CHALLENGES IN DATA INTEGRATION, AND PRODUCE SOFTWARE, PROTOCOLS, AND SOFTWARE THAT WILL BE APPLICABLE TO DIVERSE BIOLOGICAL SYSTEMS. IN LINE WITH THE CENTER'S PRIMARY GOALS, RESEARCHERS AT NYGC ALSO CONTINUED TO DEVELOP AND DEPLOY PIONEERING MULTIMODAL SINGLE-CELL TECHNOLOGIES: - THE SATIJA LAB ISSUED VERSION 4.0 OF SEURAT, ITS OPEN-SOURCE SOFTWARE TOOLKIT THAT HARMONIZES AND INTEGRATES MULTIPLE SINGLE-CELL DATASETS. - CITE-SEQ, THE MULTI-DIMENSIONAL RNA SINGLE-CELL ANALYSIS TOOL DEVELOPED AT NYGC, IS WIDELY USED BY THE SCIENTIFIC COMMUNITY AND CONTINUES TO BE EXPANDED UPON. - ECCITE-SEQ, THE EXTENSION OF CITE-SEQ FOR USE WITH CRISPR SCREENS, DEVELOPED IN 2019 BY THE SATIJA LAB AND THE NYGC TECHNOLOGY INNOVATION LAB IN COLLABORATION WITH THE SANJANA LAB IS ONE OF THE KEY TOOLS USED IN CRISPR COVID-19 SCREEN STUDY CO-LED BY THE SANAJA LAB AND PUBLISHED IN CELL IN 2020. - NYGC'S TECHNOLOGY INNOVATION LAB RELEASED ASAP-SEQ, WHICH EXTENDS THE TOOL FOR USE IN SINGLE-CELL ATAC-SEQ, A TECHNIQUE USED IN MOLECULAR BIOLOGY TO ASSESS GENOME-WIDE CHROMATIN ACCESSIBILITY. IN 2020, NYGC CORE FACULTY MEMBER, DR. DAN LANDAU, WAS NAMED A VALLEE SCHOLAR AND RECEIVED A SONTAG FOUNDATION DISTINGUISHED SCIENTIST GRANT, BOTH AWARDS IN SUPPORT OF RESEARCH THAT USES SINGLE-CELL ANALYSIS TECHNOLOGIES. ONE OF THE TOOLS THAT HIS STUDY TEAM DEPLOYS IN THIS RESEARCH IS GENOTYPING OF TRANSCRIPTOMICS, A METHOD DEVELOPED IN 2019 IN A RESEARCH COLLABORATION JOINTLY SUPERVISED AT THE NYGC. EARLY IN 2020, NYGC'S CLINICAL LAB RECEIVED APPROVAL FROM THE NY STATE DEPARTMENT OF HEALTH (NYSDOH) TO RUN ITS CLINICAL CONSTITUTIONAL WHOLE GENOME SEQUENCING (WGS) TESTING ON THE ILLUMINA NOVASEQ PLATFORM. IN DECEMBER, IT WAS ANNOUNCED THAT THE NYGC WILL SEQUENCE THE WHOLE GENOMES OF THOUSANDS OF PATIENTS RECEIVING CARE AT WEILL CORNELL MEDICINE (WCM) AND NEW YORK-PRESBYTERIAN (NYP), MAKING THIS ONE OF THE LARGEST CLINICAL WHOLE GENOME SEQUENCING PROGRAMS IN THE COUNTRY. THE NYGC CLINICAL LAB'S BOARD-CERTIFIED MOLECULAR GENETICISTS WILL INTERPRET AND RETURN THE RESULTS TO PHYSICIANS, WHO MAY THEN SHARE THEM WITH THEIR PATIENTS. THE INITIATIVE, WHICH ALSO INCLUDES A PARTNERSHIP BETWEEN WCM, NYP, AND ILLUMINA, HAS BEEN ESTABLISHED TO STUDY THE FEASIBILITY AND VIABILITY OF A LARGE-SCALE IMPLEMENTATION OF WHOLE-GENOME SEQUENCING WITHIN A MAJOR METROPOLITAN HEALTH CARE SYSTEM IN THE UNITED STATES. THE NYGC WAS THE FIRST SEQUENCING CENTER IN THE COUNTRY TO OBTAIN REGULATORY APPROVAL FOR CLINICAL WHOLE GENOME SEQUENCING TESTS FOR GENETIC DISEASES AND CANCER FROM THE NYGS OOH , WHICH HAS BEEN ACTIVE SINCE 2018. RESEARCH SEQUENCING ------------------- NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SIX YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 77,000 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE OVER 40,000 GENOMES A YEAR. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 11,000 SAMPLES IN 2020, INCLUDING 8,171 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), 356 EXOME SEQUENCING SAMPLES, AND 2,390 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. AMONG OTHER LARGE COLLABORATIVE PROJECTS, SINCE 2016 NYGC HAS BEEN AWARDED $48 MILLION FROM THE NHGRI AS ONE OF THE CENTERS FOR COMMON DISEASE GENOMICS (CCDG) FOR WHOLE GENOME SEQUENCING. THROUGH THIS AWARD, ALONG WITH THE GENEROUS PHILANTHROPIC CONTRIBUTIONS FROM OUR DONORS, THE NYGC HAS TAKEN ADVANTAGE OF ITS CLINICALLY FOCUSED, COLLABORATIVE STRUCTURE WITH THE GOAL OF ACHIEVING A COMPREHENSIVE UNDERSTANDING OF DIFFERENT TYPES OF COMMON DISEASES, WITH A CENTER-SPECIFIC FOCUS ON AUTISM. AS A MEMBER OF THIS MULTI-INSTITUTIONAL CONSORTIUM, THE NYGC LEADS AND ENABLES COLLABORATION, COMMUNICATION, AND ANALYSIS BETWEEN CENTERS AND PRINCIPAL INVESTIGATORS, PARTICIPATING IN NUMEROUS WORKING GROUPS, STEERING COMMITTEES, AND CONFERENCES AS WELL AS LEADING THE NEUROPSYCHIATRIC WORKING GROUP WHICH SPANS THREE INSTITUTIONS AND SEVERAL DISORDERS. IN 2020 NYGC COMPLETED THE SEQUENCING PORTION OF THIS PROJECT, HAVING COMPLETED MORE THAN 41,000 GENOMES AND MADE THE DATA PUBLICLY AVAILABLE. THE PROJECT DATA GENERATED BY NYGC HAS ALREADY BEEN THE SOURCE FOR A LARGE NUMBER OF PUBLICATIONS. IN ADDITION, WITH AN AWARD OF SUPPLEMENTAL FUNDS NYGC IN 2020 ALSO PERFORMED WHOLE GENOME SEQUENCING OF 3,202 GENOMES FROM THE 10000 GENOMES PROJECT, CREATING A LARGE HIGH QUALITY OPEN-SOURCE DATASET OF THESE ANCESTRALLY DIVERSE REFERENCE SAMPLES FREELY AVAILABLE TO THE GENOMICS RESEARCH COMMUNITY. IN 2020 NYGC CONTINUED TO EXPAND OUR OPERATIONAL FOCUS ON SINGLE-CELL GENOMICS, MAKING AVAILABLE TO THE RESEARCH COMMUNITY THROUGH FUNCTIONAL GENOMIC COLLABORATIONS NEW CUTTING-EDGE TECHNIQUES INVENTED IN OUR INNOVATION LAB. THESE INCLUDE CITE-SEQ, A TECHNIQUE THAT ALLOWS SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS BOTH RNA ABUNDANCE AND A LARGE NUMBER OF CELL SURFACE PROTEINS. SCIENTIFIC ADVISORY BOARD --------------------- IN 2020, THE NYGC HELD TWO MEETINGS WITH ITS NEW SCIENTIFIC ADVISORY BOARD (SAB), WHICH PROVIDES STRATEGIC ADVICE AND COUNSEL IN SUPPORT OF OUR SCIENTIFIC MISSION. COMPOSED OF LEADING INTERNATIONAL GENOMIC SCIENTISTS, AND CHAIRED BY BARBARA WOLD, PHD, BREN PROFESSOR OF MOLECULAR BIOLOGY AND DIRECTOR OF MERKIN INSTITUTE FOR TRANSLATIONAL RESEARCH AT THE CALIFORNIA INSTITUTE OF TECHNOLOGY, THE 10-MEMBER SAB OFFERS GUIDANCE AND INPUT ON RESEARCH STRATEGY FROM DIVERSE PERSPECTIVES TO THE NYGC. THE WIDE-RANGING EXPERTISE OF THE ADVISORY BOARD INCLUDES QUANTITATIVE HUMAN GENETICS, NEUROGENETICS, FUNCTIONAL GENOMICS, GENOMIC TECHNOLOGY DEVELOPMENT, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, POPULATION GENOMICS, AND CANCER GENOMICS. DIVERSITY, EQUITY, AND INCLUSION --------------------- IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD CREATING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL ABILITY, AGE, OR RELIGION. NYGC'S CROSS-FUNCTIONAL DIVERSITY, EQUITY AND INCLUSION (DEI) ADVISORY GROUP, WHOSE GOAL IS TO FOSTER AND PROMOTE DIVERSITY, EQUITY AND INCLUSION THROUGHOUT ALL ASPECTS OF NYGC'S WORK AND CULTURE, HAS PROVIDED EDUCATION AND RESOURCES FOR THE NYGC COMMUNITY TO RAISE AWARENESS OF INEQUALITY, BIAS AND ISSUES AND TO ENHANCE CULTURAL COMPETENCY. EXAMPLES INCLUDE BOOK CLUBS, JOURNAL CLUBS, SMALL GROUP DISCUSSIONS AND ORGANIZATION-WIDE TRAINING ON ISSUES RELATED TO DIVERSITY AND INCLUSION. THE GROUP HAS FOSTERED AND CULTIVATED A SUPPORTIVE, WELCOMING AND INCLUSIVE CULTURE AND ENVIRONMENT AT NYGC, FOR EXAMPLE THROUGH SHOWCASING THE WORK AND SKILLS OF DIVERSE EMPLOYEES, STAFF, FACULTY AND TRAINEES, WITH MENTORSHIP CAREER PANELS, AND BY DEVELOPING WEB PAGES, ARTICLES AND COMMUNICATIONS ON DEI-RELATED TOPICS. THEY ARE ALSO WORKING TO PROMOTE AND SUPPORT AN INCLUSIVE RESEARCH AND TRAINING ENVIRONMENT, FOR EXAMPLE BY DEVELOPING AN INTERNSHIP PROGRAM FOR UNDER-REPRESENTED MINORITIES. NYGC IS COMMITTED TO ADDRESSING SYSTEMIC RACISM AND INEQUALITIES IN SCIENCE AND IN THE WORKPLACE AND WILL CONTINUE TO EXPAND ITS WORK IN ALL OF THESE AREAS.
FORM 990, PART VI, SECTION A, LINE 6	AS OF DECEMBER 31, 2020, THE CENTER HAD A TOTAL OF 20 MEMBERS, CONSISTING OF 12 INSTITUTIONAL FOUNDING MEMBERS AND EIGHT ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (8) NORTHWELL HEALTH, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) ALBERT EINSTEIN COLLEGE OF MEDICINE. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) ROSWELL PARK CANCER INSTITUTE, (5) PRINCETON UNIVERSITY, (6) HACKENSACK MERIDIAN HEALTH, (7) GEORGETOWN LOMBARDI COMPREHENSIVE CANCER CENTER, AND (8) RUTGERS CANCER INSTITUTE OF NEW JERSEY.
FORM 990, PART VI, SECTION A, LINE 7A	EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL.
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE CHIEF SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS.
FORM 990, PART VI, SECTION B, LINE 12C	NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, PRINCIPAL OFFICERS, OR MEMBERS OF A COMMITTEE TO WHICH THE BOARD HAS DELEGATED POWERS) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY MAKE A PRESENTATION AT THE BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST.
FORM 990, PART VI, SECTION B, LINE 15	FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. IN LATE 2019 NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION. RESULTS OF THIS REVIEW WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2020 AND THE COMMITTEE DISCUSSED THEM. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT (CHERYL MOORE, CAROL ASHE, ANA BASTIANI-POSNER, SOREN GERMER, KATHLEEN MCGOVERN KEARNS, ELIZABETH O'BRIEN, MICHAEL ZODY, THOMAS LEHNER AND TOM MANIATIS) WAS REASONABLE. THE AD-HOC COMPENSATION COMMITTEE DISCUSSED SENIOR MANAGEMENT COMPENSATION IN EARLY 2020. SOREN GERMER RECEIVED A SALARY INCREASE IN 2020 TO BRING HIS SALARY TO MARKET LEVELS AT THE RECOMMENDATION OF AN INDEPENDENT COMPENSATION CONSULTANT WHO PERFORMED AN EXECUTIVE TOTAL COMPENSATION STUDY FOR NYGC. THIS SALARY CHANGE WAS REVIEWED BY AN EXECUTIVE COMPENSATION COMMITTEE OF INDEPENDENT BOARD MEMBERS AND APPROVED BY THE BOARD OF DIRECTORS. THE SENIOR MANAGEMENT TEAM DID NOT RECEIVE MERIT INCREASES IN 2020. THE TOTAL COMPENSATION OF THE SENIOR TEAM REMAINED UNCHANGED EXCEPT AS INDICATED ABOVE.
FORM 990, PART VI, SECTION C, LINE 19	NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.
FORM 990, PART VII, SECTION A	IN 2020, TOM MANIATIS, PHD, SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAM AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.